胃癌病人转化生长因子β1及其受体检测的意义

目的 通过检测胃癌病人血清转化生长因子β１浓度和组织转化生长因子βⅡ型受体的ｍＲＮＡ水平,探讨它们与胃癌浸润和转移的关联性。方法 应用酶联免疫吸附法测定２９例胃癌病人和３４例对照者的血清转化生长因子β１浓度;应用点杂交法和计算机灰度扫描分析组织的ｍＲＮＡ灰度均值。结果 胃癌组的血清转化生长因子β１浓度显著高于对照组（Ｐ〈０．０５）,分化较差组、浸润组及伴有淋巴结转移组均分别明显高于分化较好组、膨胀     

胃癌中CXCR4和CD133的表达及其对淋巴转移的影响

目的:探讨CXCR4和CD133在胃癌原发灶中的表达及其对淋巴转移的影响。方法:对50例原发性胃癌原发灶和癌旁胃黏膜组织行免疫组化染色法定位检测CXCR4和CD133蛋白;选用半定量RT-PCR及Western blot法测定CXCR4和CD133 mRNA与蛋白表达量,分析两者的相关性及其与淋巴管浸润和淋巴结转移的关系。结果:CXCR4和CD133分子均定位于肿瘤细胞膜表面,极少数CXCR4位于细胞核内。胃癌组织中CXCR4和CD133表达阳性率及mRNA和蛋白的表达量均明显高于癌旁胃黏膜组织(均P<0.05);CXCR4和CD133 mRNA相对灰度值在淋巴结转移组高于无淋巴结转移组(P=0.011,P=0.038);N1组CXCR4蛋白相对灰度值明显高于N0组(P=0.023),而低于N2+N3组(P=0.008),N1组和N2+N3组CD133蛋白灰度值明显高于N0组(P=0.04,P=0.01),但N1组与N2+N3组之间无明显差异;淋巴管浸润组中的CXCR4和CD133蛋白相对灰度值均高于淋巴管无浸润组(P<0.05);在淋巴转移患者中,CXCR4和CD133蛋白相对灰度值分别与转移淋巴结数(r=0.480,r=0.426)及转移性淋巴结比率(r=0.502,r=0.489)呈正相关。结论:CXCR4和CD133在胃癌原发灶中高表达,两者呈正相关,其联合表达与转移淋巴结比率和转移淋巴结数呈正相关,推测胃癌CD133阳性细胞亚群可能在CXCR4介导下更易导致淋巴管浸润和淋巴结转移。     

胃癌侵袭性和根治手术对患者血清透明质酸浓度的影响

为研究胃癌侵袭性和根治手术对患者血清透明质酸浓度的影响,通过应用酶联免疫吸附方法(ELISA)测定20例胃,8患者血清透明质酸(hyaluronic acid,HA)浓度,结果发现,胃癌组明显高于对照组(P<0.001),BorrmannⅢ、Ⅳ组或伴有淋巴结转移组分别显著高于Borrmann Ⅰ、Ⅱ组或无淋巴结转移组(P<0.001),切除瘤体后上述各组的HA均显著下降(P<0.01～0.001)。结果提示,血清HA可能与胃癌的浸润和转移密切相关。     

胃癌组织乙酰肝素酶mRNA表达及其意义

目的　探讨胃癌组织中乙酰肝素酶mRNA表达状况与其病理特征的关系。方法　应用原位杂交技术 ,检测正常胃黏膜 11例、萎缩性胃炎伴肠上皮化生组织 10例和 5 2例胃癌组织中乙酰肝素酶mRNA的表达 ,分析其表达状况与胃癌组织分化程度、浸润深度、淋巴结转移和器官转移的关系。结果　乙酰肝素酶mRNA阳性表达在胃癌组高于正常胃黏膜和萎缩性胃炎伴肠上皮化生组 ,差异有显著性 (P <0 .0 5 )。乙酰肝素酶mRNA阳性率在胃癌浸润浆膜层组与无浆膜层浸润组分别为 5 8.1%和 0 ,两组间差异有非常显著性 (P <0 .0 0 5 ) ;在胃癌有淋巴结转移组与无淋巴结转移组分别为 5 8.5 %和 9.1% ,两组间差异有非常显著性 (P <0 .0 0 5 )。结论　乙酰肝素酶mRNA阳性表达与胃癌浸润深度、淋巴结转移有关 ,乙酰肝素酶可作为反映胃癌生物学行为的客观指标     

胃癌侵袭性及其根治手术对病人血清转化生长因子β1浓度？…

探讨转化生长因子β１对人胃癌侵袭性的作用。方法 应用酶联免疫吸附法测定２９例胃癌病人血清ＴＧＦβ１浓度。应用点杂交法分析癌灶组织的ＴＧＦβ１ｍＲＮＡ水平。结果 浸润型组或伴有淋巴结转移组的血清ＴＧＦβ１浓度和ＴＧＦβ１ｍＲＮＡ表达水平分别明显高于膨胀型组或无淋巴结转移组，切除瘤体后上述各组的血清ＴＧＦβ１浓度均明显下降。     

胃癌组织中血管内皮生长因子C的表达与淋巴结微转移的关系

目的：检测胃癌患者血管内皮因子C（VEGF-C）蛋白及mRNA在胃癌组织中的表达情况,探讨其与胃癌淋巴结微转移的关系。方法应用免疫组织化学法及RT-PCR法检测80例胃癌组织、癌旁组织及正常组织中的VEGF-C蛋白及mRNA表达情况;免疫组化法检测淋巴结微转移情况,比较有无淋巴结微转移的VEGF-C蛋白和mRNA的表达差异,明确存在的关联性。结果VEGF-C蛋白及mRNA两者在胃癌组织中明显高于癌旁组织和正常组织（P＜0.05）。结论胃癌组织中的VEGF-C蛋白及mRNA与胃癌淋巴结微转移相关,基因检测优于蛋白,可作为评价胃癌患者是否存在淋巴结微转移的优选指标。     

TFPI-2基因在胃癌组织中的表达及临床意义

目的:探讨TFPI-2基因在胃癌组织中的表达及其临床意义。方法:收集临床胃癌患者术后大体标本64例,采用免疫组织化学方法检测TFPI-2蛋白在胃癌组织和正常胃黏膜组织中的表达,采用RT-PCR法检测TFPI-2 mRNA在胃癌组织和正常胃黏膜组织中的表达。结果:TFPI-2蛋白在正常胃黏膜组织中的表达高于胃癌组织(P0.05),无淋巴结转移胃癌组织的TFPI-2蛋白表达高于有淋巴结转移的胃癌组织(P0.05)。TFPI-2 mRNA在正常胃黏膜组织中的表达明显高于胃癌组织(P0.05),无淋巴结转移胃癌组织的TFPI-2 mRNA表达高于有淋巴结转移的胃癌组织(P0.05)。结论:TPFI-2基因是胃癌发生、侵袭和转移的重要调节因子,其低表达与胃癌淋巴结转移的生物学行为密切相关。     

BRMS1在胃癌组织中的表达与淋巴结转移的关系

目的:探讨胃癌组织中乳腺癌转移抑制基因(breast cancer metastasis suppressor1,BRMS1)mRNA表达水平与胃癌淋巴结转移之间的关系。方法:根据胃癌淋巴结转移情况,将66例胃癌标本分为转移组(46例)和未转移组(20例);以β-actin为内参照,用半定量RT-PCR方法检测66例胃癌组织中BRMS1 mRNA的表达。结果:BRMS1 mRNA在胃癌组织中的表达为0.441±0.096;BRMS1 mRNA在胃癌淋巴结转移组和未转移组中的表达分别为0.405±0.072、0.525±0.091,转移组BRMS1 mRNA的表达水平显著低于未转移组(P<0.05)。结论:BRMS1 mRNA在胃癌组织中的表达水平与淋巴结转移呈负相关,而与病理类型、分化程度无相关性。     

CD_(15)和P_(-gp)在胃癌组织中表达的临床意义

目的:探讨胃癌CD_(15)表达的意义及其与P-gp表达之间的关系。方法:应用微波-LSAB免疫组织化学法对95例胃癌组织进行CD_(15)和P-gp检测。结果:CD_(15)和P-gp表达阳性率分别为86.3％和70.7％。CD_(15)和P-gp均与肿瘤浸润、转移相关。CD_(15)阳性表达率在胃癌浸润至肌层和浆膜层者明显高于浸润至粘膜层及粘膜下层(P<0.05),伴有淋巴结转移组明显高于无转移组(P<0.05)。P-gp阳性表达率在胃癌浸润至浆膜层者明显高于浸润至肌层和粘膜层及粘膜下层者(P<0.05),伴有淋巴结转移组明显高于无转移组(P<0.05)。CD_(16)表达与P-gp表达有一定关联。结论:CD_(15)与P-gp在胃癌表达具有一致性。     

胃癌组织中CD133的表达及其临床意义

目的研究胃癌组织中CD133表达的相互关系,重点明确术前、术后外周血单核细胞中CD133mRNA表达的临床意义及其与胃癌原发灶CD133表达的关系。方法 50例胃癌、10例胃溃疡穿孔及10名健康自愿者入组研究。胃癌患者术前和术后1周抽外周静脉血各4 ml,密度梯度离心法分离单核细胞,半定量逆转录聚合酶链反应(RT-PCR)检测CD133 mRNA表达水平。胃溃疡穿孔患者术前抽外周静脉血、健康自愿者抽晨血各4 ml。胃癌原发灶及癌旁正常胃黏膜组织分别行RT-PCR、免疫组织化学染色检测CD133 mRNA和蛋白的表达。分析CD133表达对各临床病理特征和预后的影响。结果健康自愿者及术前胃溃疡患者及胃癌患者外周血中CD133 mRNA的半定量值分别为0.029±0.060、0.059±0.099及0.270±0.163(P=0.000)。胃癌患者术前外周血CD133 mRNA表达与肿瘤组织分化程度、淋巴管浸润、肿瘤浸润深度、淋巴结转移及TNM分期均有关(P<0.05)。相关分析显示,胃癌患者术前外周血中CD133 mRNA半定量值与淋巴结转移率(rs=0.422,P=0.002)、癌转移淋巴结枚数(rs=0.398,P=0.004)呈正相关,并与胃癌原发灶中CD133 mRNA的表达呈正相关(rs=0.337,P=0.017)。胃癌原发灶中CD133蛋白表达阳性者,术前外周血中CD133 mRNA的半定量值较CD133蛋白表达阴性者高(Z=-2.539,P=0.011)。50例胃癌患者行胃癌根治术后1周,其外周血中CD133 mRNA半定量值明显高于术前CD133 mRNA的表达水平(P=0.021)。胃癌浸润深度较深者,术后CD133 mRNA表达升高更明显(Z=-1.978,P=0.039)。术后外周血中CD133 mRNA高表达者较低表达者预后更差(χ2=6.193,P=0.013)。结论胃癌患者术前外周血高表达CD133 mRNA,其与肿瘤分化程度、淋巴管浸润、肿瘤浸润深度、淋巴结转移、TNM分期及胃癌原发病灶CD133蛋白表达有关,且与淋巴结转移率、癌转移淋巴结枚数及胃癌原发灶中CD133 mRNA的表达呈正相关。术后患者外周血中CD133 mRNA半定量值较术前明显升高,这一升高提示肿瘤浸润程度较深,患者预后较差。     

次级淋巴组织趋化因子在胃癌淋巴结转移中的作用

目的：研究次级淋巴组织趋化因子（secondary lymphoid tissue chemokine,SLC)在胃癌淋巴结中的表达，以进一步阐明胃癌淋巴转移的机制。方法：用逆转录聚合酶链反应（RT－PCR）测定29例胃癌组织淋巴结中SLC mRNA的表达。结果：胃癌转移淋巴结中SLC mRNA的表达均显著低于相应的正常胃黏模组织，但其表达与病人的临床病理特征并不相关。结论：在胃癌转移淋巴结中，SLC的表达明显受抑，后者可能在胃癌的淋巴结转移中起了重要作用，提高淋巴结中SLC的表达可能成为控制胃癌转移和复发的又一关键途径。     

Evaluation of Metastatic Potential of Gastric Tumors by Staining for Proliferating Cell Nuclear Antigen and Chromosome 17 Numerical Aberrations

BACKGROUND: Aberrations in chromosome 17 are important in carcinogenesis. We recently reported that numerical aberrations in chromosome 17 were associated with tumor progression in gastric cancer. The aim of this study was to determine the biological characteristics of gastric tumor cells with chromosome 17 numerical aberrations. METHODS: Gastric tumor sections (n = 105) and metastatic lymph nodes (n = 16) were stained simultaneously for PCNA (proliferating cell nuclear antigen) and chromosome 17 centromere. Cancers were classified as follows: Group 1: PCNA(+) and numerical chromosomal aberration(+); Group 2: PCNA(-) and numerical chromosomal aberration(+); Group 3: PCNA(+) and numerical chromosomal aberration(-); and Group 4: PCNA(-) and numerical chromosomal aberration(-). RESULTS: The frequency of Group 1 cells correlated with lymphatic invasion (P < .0001), lymph node metastasis (P < .0001), and venous invasion (P < .01). The frequency of these cells in gastric lesions was lower than in metastatic lymph nodes (P < .01). Logistic regression analysis identified the depth of invasion followed by the frequency of Group 1 cells were two of the most significant independent factors that could predict lymph node metastasis and lymphatic invasion. CONCLUSIONS: The frequency of gastric tumor cells positive for PCNA and chromosome 17 numerical aberrations may be an indicator of the metastatic potential of gastric cancers.     

血小板反应素-1在胃癌及转移淋巴结中的表达及其与血管生成相关性的研究

目的检测血小板反应素-1（TSP-1）在原发性胃癌及转移淋巴结组织中的表达情况,并分析其与胃癌临床病理学参数及血管生成的关系。方法应用免疫组织化学方法检测72例成对胃癌组织、癌旁正常组织（距离癌灶≥5cm）及胃周淋巴结组织中TSP-1及血管内皮生长因子（VEGF）的表达和微血管密度（MVD）的变化。采用半定量评分系统评估染色结果,并分析TSP-1蛋白表达与VEGF、MVD及胃癌临床病理学参数的关系。结果①TSP-1蛋白在胃癌组织中表达阳性率为45．8％（33／72）,在癌旁正常组织中为90．3％（65／72）,在转移淋巴结组织中为50．8％（30／59）,其在胃癌组织和转移淋巴结组织中的蛋白表达阳性率明显低于其在癌旁正常组织中的表达阳性率呼=32．710,P=0．000;）f=25．298,P=0．000）,其在胃癌组织中的蛋白表达阳性率与其在转移淋巴结组织中的表达阳性率比较,差异无统计学意义贸X=0．327,P=0．568）。②胃癌组织中TSP-1蛋白表达阳性率与淋巴结转移有关,即在有淋巴结转移的胃癌组织中TSP．1蛋白表达阳性率明显低于其在无胃周淋巴结转移组织中的表达阳性率（Z=-2．573,P=0．010）。③TSP-1在胃癌组织及转移淋巴结组织中的蛋白表达与VEGF表达（rs=-0．309,P=0．008;rs=-0．269,P=0．040）及MVD（rs=-0．348,P=0．003;rs=-0．272,P=0．037）呈负相关。结论TSP-1在胃癌组织及转移淋巴结组织中的蛋白表达均降低且与VEGF表达和MVD呈负相关,提示TSP-1可能是一个肿瘤血管生成抑制因子。     

pN0食管癌Ivor-Lewis手术后淋巴结转移性复发的危险因素

目的 探讨pN0期食管癌病人Ivor-Lewis手术后淋巴结转移性复发的危险因素.方法 对2001年1月至2005年1月间接受Ivor-Lewis手术治疗的82例pN0期胸中段食管鳞癌病人进行前瞻性研究,用RT-PCR检测食管癌组织中淋巴管生成因子C(VEGF-C)mRNA和淋巴结组织中上皮标志物(Mucin1)mRNA的表达;Kaplan-Meier法计算复发率;Log-rank检验比较复发率;Cox回归多因素分析判定独立的危险因素.结果 42例食管癌组织中检测到VEGF-C mRNA表达;23例至少在1枚淋巴结中检测到Mucin1 mRNA表达,诊断为淋巴结微转移;手术后3年内37例发生淋巴结转移;T分期与病人3年内淋巴结转移的发生率相关(P＜0.05);有VEGF-C mRNA表达者3年内淋巴结转移发生率显著高于无VEGF-C mRNA表达者(P＜0.01);有淋巴结微转移者3年内淋巴结转移的发生率显著高于无淋巴结微转移者(P＜0.01).Cox回归分析显示T分期、食管癌组织中VEGF-C mRNA表达和淋巴结微转移是病人手术后3年内淋巴结转移的独立危险因素.结论 T分期、食管癌组织中VEGF-C mRNA表达和淋巴结微转移是pN0食管癌病人Ivor-Lewis手术后淋巴结转移性复发的独立危险因素.

Abstract：

Objective To investigate the risk factors with lymph node metastatic recurrence in patients with N0 esophageal cancer after Ivor-Lewis Esophagectomy. Methods The subjects were 82 patients with pN0 esophageal cancer who underwent Ivor-Lewis esophagectomy from January 2001 to January 2005. By using RT-PCR, VEGF-C mRNA was detected in tumor issues, and Mucin l( MUC1 )mRNA was detected in lymph nodes. The Kaplan-Meier method was used to calculate the survival rate and lymph nodal metastatic rate. Log-rank test was performed to compare the recurrence rate, and Cox regression multivariate analysis was performed to determine independent prognostic factors. Results VEGF-C mRNA was identified in 42 patients (51.22%), and MUC1 mRNA was identified in 23 patients(28.05% )from at least 1 lymph node station . The diagnosis of lymph node micrometastasis (LNMM) was based on the detection of MUC1 mRNA. The first recurrence exhibiting lymph node metastasis was recognized in 37 patients (45.1%) at the first 3 years after operation and this was significantly associated with T status ( P ＜ 0. 05 ). Lymph node metastatic rate for patients with VEGF-C mRNA expression in tumor issues was significantly higher than that for patients without VEGF-C mRNA expression( P ＜0. 01 ). And lymph node metastatic rate for patients with LNMM was significantly higher than that for patients without LNMM ( P ＜0. 01 ). The results of multivariate analysis confirmed that T status, VEGF-C mRNA expression in tumor issues and LNMM were independent relevant factors. Conclusion Status,VEGF-C mRNA expression in tumor issues and LNMM in patients with N0 esophageal cancer were independent risk factors for 3-year lymph node metastatic recurrence after Ivor-Lewis Esophagectomy.     

Most Important Lymph Node Information in Gastric Cancer: Multivariate Prognostic Study

Background: In gastric cancer, the level and number of lymph node metastases is useful for predicting survival, and there are several staging systems for lymph node metastasis. The aim of this study was to compare the several lymph node classifications and to clarify the most important lymph node information associated with prognosis using multivariate analysis.Methods: A total of 106 patients with histologically node-positive gastric cancer treated by radical gastrectomy and extended lymph node dissection (D2, D3) were studied. The level of lymph node metastasis was categorized simply as Level I nodes (perigastric, No.1–6), Level II nodes (intermediate, No.7–9), and Level III nodes (distant, No.10–16), irrespective of the tumor location. The Level II nodes included lymph nodes along the left gastric artery, common hepatic artery, and celiac trunk.Results: Overall 5-year survival rate was 51%. Univariate analysis showed that 5-year survival rate was significantly influenced by the level of positive nodes (P < .01), total number of positive nodes (P < .01), number of positive Level I nodes (P < .01), and number of positive Level II nodes (P < .01), in addition to the tumor location (P < .05), tumor size (P < .05), gross type (P < .01), and depth of wall invasion (P < .01). Of these, independent prognostic factors associated with 5-year survival rate were the number of positive Level II nodes (0–1 vs. 2) (62% vs. 19%, P < .01) and the depth of wall invasion (within vs. beyond muscularis) (79% vs. 43%, P < .01).Conclusions: Among several staging systems for lymph node metastases, the number of positive Level II nodes provided the most powerful prognostic information in patients with node-positive gastric cancer. When there were two or more metastases in the Level II nodes, prognosis was poor even after D2 or D3 gastrectomy.     

Area of nodal metastasis and radioisotope uptake in sentinel nodes of upper gastrointestinal cancer

BACKGROUND: Sentinel node navigation surgery has been introduced for the treatment of gastrointestinal tumor. As few studies have examined relationships between metastatic area and radioisotope uptake in sentinel nodes, the present study examined this relationship for gastric and esophageal cancers. METHODS: Subjects comprised 43 patients (esophageal cancer, n = 19; gastric cancer, n = 24) with < or =3 lymph node metastases in whom sentinel node mapping with radio-guided methods was performed. Radioisotope uptake was measured after surgery for all dissected lymph nodes. Metastatic area was calculated using the following formula: metastatic area (%) = (area of metastasis/total area of lymph node) x 100. Based on radioisotope uptake, lymph nodes were divided into RI(-) and RI(+) groups. RESULTS: In 35 patients, > or =1 metastatic node was present among the sentinel nodes. In 1 patient, no sentinel nodes were detected. No lymph node metastasis was found in sentinel nodes in the remaining seven patients. Lymph nodes were diagnosed as metastatic using preoperative imaging. Mean (+/-SD) metastatic area was significantly higher for RI(-) (68.3 +/- 20.5%) than for RI(+) (15.1 +/- 20.8%; P < 0.0001). Radioisotope uptake was decreased in lymph nodes with >60% metastatic area. CONCLUSIONS: The fact that radioisotope uptake is not detectable in some lymph nodes with >60% metastatic area must be considered when planning sentinel node navigation surgery.     

P-糖蛋白在胃癌组织中的表达及临床意义

目的探讨 P-糖蛋白 ( Pgp)在胃癌组织中的表达并分析其与胃癌临床病理特点、术前化疗及预后的关系 .方法应用免疫组织化学法检测手术切除的 101例胃癌、 20例正常胃黏膜、 18例异型增生组织标本中 Pgp的表达 .结果正常胃黏膜、异型增生及未经术前化疗的胃癌中 Pgp表达依次增强 (P< 0 05);经术前化疗后胃癌 Pgp表达增强 ,且与化疗次数相关 (P< 0 05); Pgp表达与肿瘤浸润深度 (P< 0 01)、淋巴结转移 (P< 0 05)及 PTNM分期 (P< 0 05)有关;胃癌组织中 Pgp高水平表达者术后生存率较 Pgp低水平表达者为低 (P< 0 01).结论在胃癌化疗前后检测 Pgp将有助于临床上制订合理的化疗方案 ,胃癌组织中 Pgp表达水平是预测胃癌预后的一个有用指标 , Pgp高水平表达者预后较差 .     

TMSG-1在人前列腺癌细胞株与前列腺癌组织中的表达及临床意义

目的 探讨肿瘤转移抑制基因-1(TMSG-1,亦称LASS2)在人不同转移潜能前列腺癌细胞株中与前列腺癌组织中的表达及其临床意义.方法 采用实时荧光定量聚合酶链反应(PCR)及细胞爬片免疫荧光组织化学方法,检测TMSG-1在人不同转移潜能前列腺癌细胞株低转移潜能(PC-3M-2134)和高转移潜能(PC-3M-IE8)中的表达.并采用免疫组织化学方法检测TMSG-1在人前列腺增生及前列腺癌组织中的表达,同时探讨其与临床病理特征之间的关系.结果 TMSG-1在PC-3M-284细胞株中的mRNA及蛋白表达(2.70±0.30、75.26±2.68)均明显高于在PC-3M-IE8细胞株中的表达(1.10±0.20、38.08±1.84),差异有统计学意义(P＜0.05).通过免疫组织化学观察表明TMSG-1在前列腺增生及前列腺癌组织中均有表达,但在前列腺增生中的阳性表达率(32/40)明显高于在前列腺癌中的阳性表达率(21/60).两者差异有统计学意义(P＜0.05).并且TMSG-1在前列腺癌组织中的表达与年龄、Gleason分级、淋巴结转移及TNM分期密切相关(P＜0.05),而与肿瘤的大小无明显相关.结论 TMSG-1在低转移潜能前列腺癌细胞株中的mRNA及蛋白表达明显高于在高转移潜能前列腺癌细胞株中的表达,证明它是一种肿瘤转移抑制基因.TMSG-1在人前列腺增生与前列腺癌组织中的表达之间差异有统计学意义,并且TMSG-1在前列腺癌中的表达与年龄、Gleason分级、淋巴结转移及TNM分期密切相关.

Abstract：

Objective To investigate the expression of tumor metastasis suppressor gene 1 (TMSG-1 as well LASS2) in different prostate cancer cell lines and prostate cancer tissues and its clinical significance. Methods Sixty patients with prostate cancer had undergone surgery between 2008 and 2010.Forty patients with prostatic hyperplasia were chosen. Immunofluorescence histochemistry was used to study the distribution of TMSG-1 in cells, immunohistochemistry was used to observe the difference in TMSG-1 expression between prostatic hyperplasia and prostate cancer tissues, and the relationship between the TMSG-1 expression and clinicopathological features in prostate cancer tissues was analyzed. Results The level of TMSG-1 mRNA in PC-3M-2B4 cell line with low metastatic potentiality (2. 70 ±0. 30) was higher than in PC-3M-IE8 cell line (1. 10 ±0. 20). Immunofluorescence histochemistry revealed that most of the collected prostate cancers and prostatic hyperplasia tissues expressed TMSG-1 in cytoplasma, and nuclei were stained in a few of prostate cancer tissues. The average fluorescence intensity of TMSG-1 in PC-3M-2B4 cells (75. 26 ±2. 68) was obviously higher than in PC-3M-IE8 cells (38. 08 ± 1. 84). There was obviously different expression of TMSG-1 between prostate cancers (21/60) and prostatic hyperplasia ( 32/40 ) ( P ＜0. 05 ) . The TMSG-1 levels in prostate cancer tissue were significantly correlated with ages,Gleason grade, lymph node metastasis and tumor, nodes, metastasis (TNM) staging (P ＜0. 05) , but not with the size of tumor. Conclusion The expression level of TMSG-1 mRNA and protein in prostate cancer cell lines with low metastatic potentials significantly higher than in prostate carcinoma cell lines with high metastatic potentials, which proves that TMSG-1 is a tumor metastasis suppressor gene. From the difference in the TMSG-1 expression between human prostatic hyperplasia and prostate cancer tissues and the correlation with age, Gleason grade, lymph node metastasis and TNM stage in prostate cancers, we infer that TMSG-1 is an important prognostic indicator in judging prostate cancer cell growth, progression and metastasis.     

血管发生对胃癌的发展与预后的影响

目的探讨血管发生在胃癌发展和预后中的作用。方法用免疫组织化学染色法检测９８例胃癌标本的微血管计数并研究其与临床病理特征和预后的关系。结果胃癌的微血管数为１２～１１４８支,平均３１７支;女４０５支,男５２７支（Ｐ＜００１）。年龄从少到老,由４２５支增至６０６支（Ｐ＜００５）;胃癌从小长大,其微血管数由３４３增至５１４支（Ｐ＜００１）。浅表型３７６支,最少;隆起型６５５支,最多（Ｐ＜００１）。胃癌从粘膜侵入浆膜下,由２５８支增至５７８支（Ｐ＜００１）;侵入淋巴管,３６３支增至５７５支（Ｐ＜００１）;胃癌转移到淋巴结,其微血管数由４４０支增至５５９支（Ｐ＜００１）;转移到肝肺,４８４支增至７４６支（Ｐ＝００７）。本组全部胃癌患者中,从２０支以下增到６０支以上,其５年生存率由６９％（２４／３５）降到３６％（５／１４）（Ｐ＜００５）,根治性切除患者中５年生存率从７３％（２４／３３）减至２９％（５／１７）（Ｐ＜００１）。结论血管发生可能促进胃癌的发展并影响其预后。